Skip to content

Remimazolam pretreatment reduces etomidate-induced myoclonus in gastroscopy

Remimazolam pretreatment reduces etomidate-induced myoclonus in gastroscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099253
Enrollment
Unknown
Registered
2025-03-20
Start date
2025-03-24
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Etomidate-induced myoclonus

Interventions

Etomidate group:The patient was injected with 0.3 mg/kg etomigrin within one minute
Remimazolam group:7 mg is given and the injection is completed within one minute.
Remimazolam Etomibe group 1:Reimazolam 2 mg and etomigrin 0.2 mg/kg were given
Remimazolam Etomigrin group 2:Reimazolam 5 mg and etomigrin 0.2 mg/kg were given

Sponsors

Hebei University Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients aged 18-70 years with ASA grade I-II undergoing elective painless gastroscopy examination. Patients and their families are willing to accept the survey contents involved in this study.

Exclusion criteria

Exclusion criteria: American Society of Anaesthesiologists (ASA) physical status III, IV, and V; allergy to the drugs used in the study; pregnant or lactating females; adrenocortical function inhibition; psychosis; difficult airways; sleep apnea syndrome; opioid abuse; severe organ dysfunction. The patients received some sedatives or analgesics 4 weeks before the operation.

Design outcomes

Primary

MeasureTime frame
Myoclonus ;

Secondary

MeasureTime frame
Blood pressure;Hearth Rate;Blood oxygen saturation;

Countries

China

Contacts

Public ContactLiu rongfang

Hebei University Affiliated Hospital

514361422@qq.com+86 181 3275 8760

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026